| Drug Name |
Tamoxifen citrate |
| Drug ID |
BADD_D02112 |
| Description |
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].[A1026]
Tamoxifen was granted FDA approval on 30 December 1977.[L7799] |
| Indications and Usage |
Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L02BA01 |
| DrugBank ID |
DB00675
|
| KEGG ID |
D00966
|
| MeSH ID |
D013629
|
| PubChem ID |
2733525
|
| TTD Drug ID |
D07KSG
|
| NDC Product Code |
89141-123; 65319-1051; 63275-9865; 63187-976; 51407-440; 60429-910; 63739-269; 68071-5005; 59651-300; 50090-0942; 70771-1185; 71335-1424; 0591-2472; 68382-827; 0378-0144; 63739-143; 65319-1151; 46014-1180; 59651-299; 13632-654; 51927-5076; 0378-0274; 71335-0893; 51927-2976; 51407-439; 17337-0035; 51552-0838; 60429-909; 51862-642; 46014-1200; 51862-447; 51862-446; 0591-2473; 51862-682; 68382-826; 17337-0034; 51862-643; 50090-0485; 71335-0237; 46014-1190; 49452-7571; 70518-2721; 36974-0048; 46014-1015; 70771-1184 |
| Synonyms |
Tamoxifen | ICI-47699 | ICI 47699 | ICI47699 | Nolvadex | Novaldex | Tamoxifen Citrate | Citrate, Tamoxifen | Tomaxithen | Zitazonium | ICI-46474 | ICI 46474 | ICI46474 | ICI-46,474 | ICI 46,474 | ICI46,474 | Soltamox |
